4.7 Review

Optimizing Cholesterol Treatment in Patients With Muscle Complaints

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 70, Issue 10, Pages 1290-1301

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.07.752

Keywords

cardiovascular disease; low-density lipoprotein; myalgia; myopathy; statin intolerance

Funding

  1. Akcea
  2. Amgen
  3. AstraZeneca
  4. Esperion
  5. Medicines Company
  6. Regeneron
  7. Valeant
  8. Sanofi
  9. Merck Sharp Dohme
  10. Pfizer
  11. Johnson Johnson
  12. General Electric
  13. Abbott Laboratories
  14. Abbvie
  15. Serapta
  16. Medtronic

Ask authors/readers for more resources

Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms. (J Am Coll Cardiol 2017;70:1290-301) (C) 2017 by the American College of Cardiology Foundation. Published by Elsevier. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available